The LATS1 gene is a mammalian member of the novel lats tumor suppressor family. Both lats mosaic¯ies and LATS1 de®cient mice spontaneously develop tumors. Our previous studies have shown that inactivation of Drosophila lats leads to up-regulation of cyclin A in thē y, and the human LATS1 protein associates with CDC2 in early mitosis in HeLa cells, suggesting that the lats gene family may negatively regulate cell proliferation by modulating CDC2/Cyclin A activity. We demonstrate here that transduction of the human breast cancer cell MCF-7 with recombinant LATS1 adenovirus (Ad-LATS1), but not with EGFP adenovirus (Ad-EGFP), inhibits in vitro cell proliferation. Ectopic expression of LATS1 in MCF-7 cells speci®cally downregulates Cyclin A and Cyclin B protein levels and dramatically reduces CDC2 kinase activity, leading to a G2/M blockade. Furthermore, Ad-LATS1 suppresses anchorage-independent growth of MCF-7 cells in soft agar and tumor formation in athymic nude mice. We also demonstrate that ectopic expression of LATS1 in MCF-7 cells and human lung cancer cell H460 upregulates the level of BAX proteins and induces apoptosis. Finally, we show that LATS1 kinase activity is required for its ability to inhibit cell growth and induce apoptosis. The results indicate that the LATS1 tumor suppressor may play an important role in the control of human tumor development and that LATS1 suppresses tumorigenesis by negatively regulating cell proliferation and modulating cell survival.
Introduction lats (also known as warts), a novel tumor suppressor family, encodes a class of putative Ser/Thr protein kinases. The lats gene was ®rst identi®ed as a tumor suppressor in Drosophila (Justice et al., 1995; Xu et al., 1995) . Somatic cell mutants for lats undergo extensive proliferation and form large tumors in many tissues in mosaic¯ies. Homozygous mutants display a wide range of developmental defects including embryonic lethality (Xu et al., 1995) .
LATS1 or Warts1 (Nishiyama et al., 1999 ) is a mammalian homolog of Drosophila lats. Expression of the human LATS1 gene in Drosophila rescues all developmental defects in homozygous Lats mutants and suppresses tumor formation in lats mosaic ies . Lats1-de®cient female mice spontaneously develop large soft tissue sarcomas and ovarian stromal cell tumors, demonstrating that Lats1 is, at least in mice, a tumor suppressor . The human LATS1 gene has been mapped to chromosome 6q24 ± 25 (Nishiyama et al., 1999) where loss of heterozygosity has been observed in ovarian (Cooke et al., 1996; Lee et al., 1990) , cervical (Mazurenko et al., 1999) , and breast cancers (Fujii et al., 1996; Theile et al., 1996) . Mutation analyses on 25 breast cancer samples found no mutation in the LATS1 coding region, but it is still possible that LATS1 may be inactivated in human breast tumors by other epigenetic mechanisms such as methylation (Morinaga et al., 2000) . During mitosis LATS1 associates with zyxin, a component of focal adhesion, in the mitotic apparatus. Microinjection of a truncated human LATS1 protein (a.a 136 ± 700) interfered with the localization of zyxin to the mitotic apparatus and elongated mitosis . LATS2 (Yabuta et al., 2000) , also known as KPM (Hori et al., 2000) , is the second mammalian member of the lats tumor suppressor gene family but the physiological function of LATS2 is unknown.
Although both Drosophila lats and mouse Lats1 suppress tumor formation in fruit¯ies and mice, respectively, the role of LATS1 in human tumorigenesis is not yet clear, nor are the mechanism(s) by which LATS1 controls tumor development. Our previous studies showed that loss of function of lats in Drosophila results in up-regulation of Cyclin A and that LATS1-associated CDC2 lacks kinase activity in HeLa cells Turenchalk et al., 1999) , suggesting that the lats gene family may control tumor development by negatively regulating cell proliferation.
Here, we further demonstrate that LATS1 inhibits cell proliferation by blocking the G2/M transition. Our studies reveal that the ectopic expression of LATS1 in the human breast cancer cell line, MCF-7, speci®cally down-regulates mitotic cyclins and CDC2/Cyclin kinase activity. Our results also show that the Ad-LATS1-transduced MCF-7 cell lose tumorigenicity. In addition, we show that ectopic expression of LATS1 in MCF-7 cells and human lung cancer cell H460 upregulates the level of BAX proteins and induces apoptosis. Finally, we demonstrate that LATS1 kinase activity is required for its ability to inhibit cell growth and induce apoptosis.
Results
The expression of exogenous LATS1 gene in the human breast cancer cell MCF-7
To express the human LATS1 gene in MCF-7 cells and easily monitor the cells expressing LATS1, we generated one control adenovirus, Ad-EGFP, and three recombinant adenoviruses which express LATS1 and its mutants by modifying a pre-existing adenovirus expression system ( Figure 1a , also see Materials and methods). The LATS1 and EGFP genes are expressed as a bicistron, separated by IRES. The infection eciency of the adenovirus can be easily monitored by EGFP, and transduced cells can be enriched by FACS for analysis. Expression of the endogenous LATS1 protein in MCF-7 cells is very low and can only be detected by immunoprecipitation/Western blot with anti-LATS1 antibodies (lanes 1 and 2, Figure 1b) . However, the exogenous human LATS1 protein is easily detected by direct Western blot in Ad-LATS1-transduced MCF-7 cells (lane 4, Figure 1b ).
LATS1 suppresses tumorigenicity of MCF-7 cells
To test whether expression of LATS1 suppresses tumorigenicity of human tumor cells, the human breast cancer cell line, MCF-7, was infected with either Ad-LATS1 or control virus Ad-EGFP. Anchorage-independent growth of MCF-7 cells expressing exogenous LATS1 was measured in soft agar and tumor development in nude mice was examined. As shown in Figure 2a , Ad-LATS1 signi®cantly suppressed colony growth of MCF-7 cells in soft agar as compared to control virus Ad-EGFP. Six of six mice in which the Ad-EGFP-transduced cells were injected displayed tumor growth within 10 weeks. In contrast, six of six mice injected with Ad-LATS1 transduced cells were tumor free 10 weeks after inoculation. These studies demonstrate that ectopic expression of LATS1 suppresses the anchorage-independent growth of MCF-7 cells in soft agar and tumorigenicity of MCF-7 cells in vivo, indicating the LATS1 may play a role in human tumor development control.
Expression of LATS1 inhibits the growth of MCF7 cells and blocks cells at G2/M
The eects of ectopic expression of LATS1 on cell growth were examined to investigate the mechanism(s) by which the expression of LATS1 suppresses tumorigenicity of MCF-7 cells. The growth curve of Ad- (Figure 2b ). This result suggests that the growth of Ad-LATS1-transdcued MCF-7 cells was strongly inhibited by the transiently expressed LATS1 protein. The eect of ectopic expression of LATS1 on the cell cycle progression of MCF-7 cells was then examined by FACS. As shown in Figure 2c , expression of LATS1 resulted in a dramatic decrease (from 59%+6 to 31%+3) in the G1 cell population and a signi®cant increase (from 27%+4 to 36%+4) in the G2/M cell population at day 3 post-virus infection. These results indicate that ectopic expression of LATS1 suppresses cell growth by either blocking the cell cycle at G2/M or delaying mitosis.
To con®rm that expression of exogenous LATS1 results in a G2/M arrest or a delay of mitosis, MCF-7 cells infected with Ad-LATS1 or Ad-EGFP were ®rst synchronized at G1/S transition by serum starvation and aphidicolin treatment (see Materials and methods). The cell cycle progression of the cells released from G1/S block was examined by DNA content FACS analysis (Figure 3a) . Results showed that both Ad-LATS1 and Ad-EGFP-transduced cells entered S phase almost at the same time (Figure 3a , 2.5 h) after Then, the cells were harvested for DNA content analysis at indicated time points after release from aphidicolin-mediated arrest at the G1/S transition. At 0 h, when aphidicolin was removed, cells had 2n DNA content. As they progressed into S phase, the¯uorescence intensity per cell increased (peak shift to the right) to give 42n but 54n. (b) Cell cycle progress of the BrdU-pulse-labeled MCF-7 cells infected by Ad-LATS1 or Ad-EGFP. The cells were ®rst pre-treated identically as (a). One hour after release from aphidicolin blocking, cells were labeled with 1 mM BrdU for 2.5 h at 378C. At the end of labeling, cells were either harvested immediately (3.5 h point) or grown in BrdU-free medium for an extra 8.5 h (12 h point) or 20.5 h (24 h point). Harvested cells were stained with an anti-BrdU antibody and 7AAD using a BrdU labeling kit (PharMingen), and analysed according to manufacturer's instruction. To simplify analysis, BrdU labeled cells were divided (boxed) into two parts: G1/early S phase and later S phase/G2/M. Percentage, the average of the three experiments, of the BrdU positive cells for each part are indicated above each box. (c) Mitotic indices in Lats1-transduced MCF-7 cells. The cells were treated the same as (b). At indicated times after removal of aphidicolin, the cells were ®xed by 4% paraformaldehyde and stained with propidium iodide. Mitotic index was determined by counting the percentage of cells with condensed chromatin under¯uorescent microscope. An average total of 400 cells were counted for Lats1-transduced MCF-7 cells or control cells at each time point. All experiments were repeated three times. The time points indicated in each panel are the point when cells were harvested after removal of aphidicolin (release from G1/S block) for further analysis. 7AAD: 7-aminoactinomycin D, BrdU: Bromodeoxyuridine removal of aphidicolin, at 9 h both populations of cells began entering G2/M, and by 12 h the majority of cells were in G2 or mitosis. However, as shown in Figure  3a , while most Ad-LATS1-transduced cells were at G2/ M or in late S phase 12 h after removal of aphidicolin, about 34% of the Ad-EGFP-transduced MCF-7 cells were in G1 or early S phase ( Figure 3a , 12 h) (see discussion for a possible explanation). This retained G1 population in the Ad-EGFP-transduced cells interferes with the quantitative analysis of cell cycle progression on steady-state MCF-7 cells infected by Ad-EGFP.
To eliminate this interference and ascertain the role of LATS1 in the control of either G2/M transition and/or mitosis, we analysed the cell cycle progression of the BrdU-pulse-labeled cells that would start from an early S phase (Figure 3b ). One hour after removal of aphidicolin, Ad-LATS1 or Ad-EGFP-infected cells were pulse-labeled with BrdU for 2.5 h and harvested for FACS analysis at the indicated time points in Figure 3b (see Materials and methods). As expected, the majority of BrdU-labeled cells (65%+2 Ad-LATS1-transduced cells and 69%+1 control cells) were in early S phase at the end of BrdU labeling (3.5 h in Figure 3b) . After 24 h, 74%+6 of the BrdUlabeled Ad-EGFP transduced-cells ®nished the cell cycle and re-entered G1, and 26%+6 of them were at G2/M or late S phase. However, after 24 h, 62%+3 of the Ad-LATS1-transduced cells were still retained at G2/M or late S phase (Figure 3b) . These results together with results shown in Figure 2c and Figure 3a clearly demonstrate the ectopic expression of LATS1 in MCF-7 cells results in an arrest at G2/M or a delay in mitosis.
To distinguish whether ectopic expression of LATS1 blocks G2/M transition or delays progress of mitosis, mitotic index was counted for synchronized LATS1-transduced MCF-7 cells and the control. Results in Figure 3c showed that *20% of EGFP-transduced control cells were in mitosis 12 h after removal of aphidicolin and mitotic index reached its maximum around 12.75 h. However, only 42% of LATS1-transduced cells went into mitosis at all the time points examined after removal of aphidicolin. These results demonstrate that ectopic expression of LATS1 blocks G2/M transition.
LATS1 modulates the expression of Cyclin A and B
To understand the mechanism of LATS1-mediated G2/ M blockade, we further examined whether the expression of LATS1 aects the cell cycle regulators implicated in the G2/M transition. Figure 4a showed that the ectopic expression of LATS1 in MCF-7 cells resulted in the down-regulation of Cyclin A and Cyclin B, while there was no eect on the cell cycle regulators, Cyclin E, CDC2, CDK2, P27 KIP and p21 CIP . The decrease in protein levels of Cyclin A and Cyclin B became obvious at day 2 after virus infection. By day 3, Cyclin A and Cyclin B were almost completely degraded. H1 kinase assay showed that the kinase activity of CDC2/Cyclin B in LATS1-transduced MCF-7 cells was dramatically reduced (Figure 4b ). These results indicate that the G2/M block of LATS1-transduced cells may result from LATS1-mediated down-regulation of activity of CDC2/Cyclin B and CDC2/Cyclin A (see discussion).
LATS1 induces apoptosis of MCF-7 cells
Three days after virus infection 25%+3 of Ad-LATS1-transduced MCF-7 cells were in sub-G1, while only 8%+2 of Ad-EGFP transduced cells were in sub-G1 (Figure 2c ). This suggests that ectopic expression of LATS1 causes apoptosis. This is consistent with our observation that a large number of MCF-7 cells detached from the plate and died after infection of Ad-LATS1 (data not shown). Further FACS analysis revealed that the percentage of Ad-LATS1-transduced MCF-7 cells in sub-G1 phase further increased from 25%+3 at day 3 to 50%+2 at day 4 after virus infection. This is 3.8-fold higher than that in the Ad-EGFP-infected cells (Figure 5a ). TUNEL (terminal deoxynucleotidyl transferasemediated dUTP-X nick end-labeling) assay was also performed to con®rm DNA fragmentation. 65%+6 of Ad-LATS1-transduced MCF-7 cells were positive in the TUNEL assay, but only 12%+3 of the Ad-EGFPinfected cells were positive (Figure 5b ). To ascertain that expression of exogenous LATS1 induces apoptosis, adherent MCF-7 cells at day 4 after virus infection were harvested to examine evidence for earlier apoptosis using the Annexin V assay. We found that 44.7%+2 of the Ad-LATS1-transduced cells were positive for Annexin V staining but negative for 7AAD staining, almost threefold higher than that of Ad-EGFPtransduced cells (Figure 5b ). To gain mechanistic insight into LATS1-mediated apoptosis, the levels of several proteins that are involved in the regulation of apoptosis were examined. As shown in Figure 5d , the level of BAX protein in Ad-LATS1-transduced MCF-7 cells signi®cantly increased, compared with that of Ad-EGFP-transduced cells. Levels of BCL-x L and BCL2 (data not shown) remained unchanged. LATS1-mediated up-regulation of BAX was also con®rmed in human non-small lung cancer cell, H460 (Figure 5e ), which went into apoptosis after Ad-LATS1 transduction (data not shown). Quantitative real-time PCR (TaqMan) analysis showed that BAX mRNA in LATS1-transduced MCF-7 cells was not signi®cantly altered with respect to the EGFP-transduced control cells (data not shown). This result agrees with the observation that the expression of P53, a transcriptional activator of BAX, was not changed in LATS1-transduced MCF-7 cells with respect to the control (Figure 5d ). Compared with the non-transduced or mutant LATS1 (LATS1 K734M )-transduced H460 cells, expression of P53 did not increase in LATS1-transduced cells (data not shown). These results suggest that Lats1-mediated up-regulation of BAX neither relies on p53-mediated activation of the BAX gene nor acts at the transcriptional level in MCF-7 cells.
The kinase activity of the LATS1 protein is required to induce apoptosis and inhibit cell growth LATS1 encodes a putative Ser/Thr kinase and the LATS1 protein is phosphorylated in a cell cycledependent manner (Nishiyama et al., 1999; . To test whether the kinase activity of the LATS1 protein is necessary for cell growth inhibition and induction of apoptosis in MCF-7 cells, two mutants, LATS1 K734M and LATS1 S909A (Figure 1a ), were generated. Lys 734 of LATS1 is conserved in the kinase domain of all Ser/Thr kinases (equivalent to Lys72 de®ned in Hanks et al). This conserved Lys residue has been proven to play a key role in the recognition of the phosphate group of Mg-ATP (Hanks et al 1988) . Changing this Lys residue usually results in a kinase-inactive protein. Overexpression of LATS1 K734M neither signi®cantly increases apoptosis in MCF-7 cells compared with Ad-EGFP infected cells (Figure 6a ) nor does it up-regulate the BAX protein (Figure 5d ,e). Ser 909 of LATS1 is another residue conserved in sub-domain 8 of the kinase domain (Hanks et al 1988) . This conserved amino acid residue is usually phosphorylated to regulate kinase activity. As shown in Figure 6a , ectopic expression of LATS1 S909A also failed to induce apoptosis of MCF-7 cells. The growth inhibition assay also demonstrates that LATS1 mutant proteins, LATS1 K734M and LATS1 S909A , lose their ability to inhibit cell growth (Figure 6b ). We conclude that the putative kinase activity of LATS1 is required for the induction of apoptosis and inhibition of cell proliferation.
Discussion
Previously, we have shown that Drosophila lats and mouse Lats1 genes are involved in suppressing tumor development in¯ies and mice, respectively Xu et al., 1995) . However, the function of LATS1 in human tumorigenesis and the mechanism(s) by which the lats genes suppress tumor development has not been elucidated. Our study presented demonstrates that ectopic expression of LATS1 in the human breast cancer cell MCF-7 signi®cantly suppresses their colony-forming ability in soft agar and tumor development in athymic nude mice. Therefore, the human LATS1 gene may also play an important role in suppressing tumor formation in humans.
The LATS1 protein is associated with CDC2 in HeLa cells and is phosphorylated at the G2/M transition or in early mitosis (Nishiyama et al., 1999; Tao et al., 1999) . Loss of function in Figure 6 LATS1 kinase activity is required to induce apoptosis and inhibit cell growth. MCF-7 cells were infected with an adenovirus expressing wild type LATS1 or its mutants, LATS1 K734M or LATS1
S909A
, or Ad-EGFP. Four days later, the Annexin V assay was performed to determine the population of apoptotic cells (a). The virus infected cells were re-seeded after infection and counted daily. Cell numbers seeded at day one and total cell numbers at day 10 were shown (b). All experiments were repeated three times Drosophila lats leads to up-regulation of Cyclin A . Based on these ®ndings, it was proposed that the lats gene regulates the cell cycle by modulating CDC2/Cyclin A activity . Here we prove that human LATS1 plays an important role in the regulation of cell proliferation. We found that ectopic expression of LATS1 in MCF-7 cells inhibits growth (Figure 2b) . The cell cycle pro®le analyses of asynchronized ( Figure 2c ) and synchronized ( Figure  3a) LATS1-transduced MCF-7 cells together with BrdU-pulse-labeling experiments (Figure 3b ) strongly suggest that expression of LATS1 may arrest the cell cycle at G2/M and/or delay progress of mitosis. Mitotic index counting experiments showed that the majority of LATS1-transduced MCF-7 cells did not enter mitosis after release from G1/S block, proving that expression of LATS1 in MCF-7 cells blocks G2/M transition rather than delaying progress of mitosis. LATS1 was thought to be involved in controlling mitotic progress based on the observation that microinjection of a truncated LATS1 protein (a.a. 136 ± 700) into HeLa cells interfered with the localization of zyxin to the mitotic apparatus and resulted in a delayed exit from mitosis . However, the truncated LATS1 protein acts as a dominant negative form causing disruption of normal function of the endogenous LATS1 protein. The LATS1 protein ectopically expressed in MCF-7 cells is wild type full-length and did not disrupt the function of endogenous LATS1 in mitosis. LATS1-transduced MCF-7 cells were blocked at G2/M (Figure 3c ) rather than in mitosis. We found that expression of kinase inactive proteins, LATS1 K734M and LATS1 S909A , in MCF-7 cells neither resulted in signi®cant suppression of cell growth (Figure 6b ) nor signi®cant changes in cell cycle pro®les (data not shown). Therefore, more investigation is needed to de®ne the role of LATS1 in the control of the progression of mitosis.
Although both DNA content analysis (Figure 3a , 2.5 h) and BrdU-pulse-labeling experiments (Figure 3b , 3.5 h) showed that there is no signi®cant dierence for initiation of DNA synthesis between LATS1-transduced and control cells (Figure 3a , 2.5 h and Figure  3b , 3.5 h), there is an accumulation (*17% more) of LATS1-transduced cells in early S phase (Figure 3b , 12 h). These data suggest expression of LATS1 might also reduce the rate of DNA synthesis or cause a partial arrest at S to G2 transition. More detailed investigations will be helpful to understand the role of LATS1 in S phase.
The percentage of Ad-LATS1 and Ad-EGFP infected MCF-7 cells in S phase (6% and 8%, respectively, Figure 2c ) is lower than that of uninfected control MCF-7 cells (*10%, data not shown). A possible explanation is that adenovirus infection aects cell proliferation since we have observed that the control virus Ad-EGFP-infected MCF-7 cells grew much slower than uninfected cells (unpublished data). About 38% of BrdU-labeled Ad-LATS1 transduced cells re-entered G1 24 h after the removal of aphidicolin (Figure 3b ). Since about 15% of the MCF-7 cells were not transduced by Ad-LATS1, and were therefore not subjected to LATS1-mediated cell cycle perturbation, we estimate that only about 23% of BrdU-labeled cells escaped LATS1-mediated G2/M arrest, completed mitosis and re-entered G1. These results suggest that LATS1-mediated G2/M arrest may not be complete.
Further molecular studies reveal that ectopic expression of LATS1 in MCF-7 cells resulted in speci®c downregulation of protein levels of Cyclin A and Cyclin B, while no eect was found on cyclin E, CDC2, CDK2, p27 KIP , and p21 CIP levels (Figure 4a ). Our studies also showed that the kinase activity of CDC2/Cyclin B (Figure 4b ) was signi®cantly reduced in Ad-LATS1-infected MCF-7 cells. We infer that CDC2/Cyclin A activity was also lost or signi®cantly down-regulated as Cyclin A was signi®cantly degraded (Figure 4a ). Whether expression of LATS1 directly or indirectly leads to the down-regulation of Cyclin A and B is currently unknown. Cyclin B (Murray et al., 1989) and Cyclin A (Furuno et al., 1999) are the rate-limiting components required for entry into mitosis. Nondegradable mutants Cyclin A or B prevent exit from mitosis with elevated levels of kinase activity (Hunter and Pines, 1994; King et al., 1996; King et al., 1994) . We proposed that expression of LATS1 induces cell cycle arrest at G2/M in mammalian cells by down-regulating CDC2/Cyclin A and/or CDC2/Cyclin B kinase activities. This mechanism is dierent from that observed in Drosophila, where Drosophila lats genetically interacts only with cdc2 and cyclin A genes and regulates the expression of cyclin A while it does not interact with cyclin B, cyclin E, and cdc2c .
As shown in Figure 3a , while most Ad-LATS1 transduced cells were at G2/M or in late S phase 12 h after the removal of aphidicolin, about 34% of the Ad-EGFP-transduced MCF-7 cells were in G1 (Figure 3a , 12 h). A possible explanation is incomplete synchronicity of serum starvation/aphidicolin treatment. It has been reported that serum starvation/aphidicolin treatment only resulted in 80% G1/S block in NIH3T3 cells (Wright et al., 1999) . We also found that only 65%+4 of MCF-7 cells were synchronized at the G1/S transition after serum starvation/aphidicolin treatment (Figure 3a, 0 h ). The retained G1 population in the Ad-EGFP-transduced cells at 12 h could result from those asynchronized cells that were already in S and G2/M at the end of aphidicolin treatment. The asynchronized cells continually went through mitosis and re-entered G1 after the removal of aphidicolin. However in Ad-LATS1-transduced MCF-7 cells, those that were not synchronized at the G1/S transition were unable to re-enter G1 as quickly as the control cells because of LATS1-mediated blockage at G2/M. This is supported by our observation that only a very small number of LATS1-transduced MCF-7 cells entered into mitosis (Figure 3c ).
In addition to negatively regulating the cell cycle, tumor suppressors are directly involved in the regulation of apoptosis that keeps tumor growth in check. Such tumor suppressors include p53 (Sheikh and Fornace, 2000) , PTEN (Di Cristofano et al., 1999; LATS1, tumor suppressor, G2/M arrest, apoptosis H Xia et al Stambolic et al., 1998) , APC (Morin et al., 1996) and PML (Le et al., 1998; Wang et al., 1998) . Ectopic expression of either p53 (Sheikh and Fornace, 2000; Taylor and Stark, 2001) or a target gene of p53, MCG10 (Zhu and Chen, 2000) , resulted in a cell cycle arrest at G2/M and apoptosis. We show that ectopic expression of LATS1 in MCF-7 cells induces apoptosis, suggesting that the LATS1 gene may also play a tumor suppressor function by regulating apoptotic signals. We found that ectopic expression of Lats1 in both human breast tumor cell MCF-7 and NSCLC cell H460 signi®cantly up-regulates the level of BAX, a pro-apoptotic protein (Figure 5d ,e), while the levels of anti-apoptotic proteins such as BCL-x L and BCL2 remained unchanged. P53 has been well documented as a transcriptional activator of BAX (Miyashita and Reed, 1995) . However, recent studies on the expression and mutation of BAX and P53 in human primary breast tumors (Sturm et al., 2000) and pulmonary artery sarcomas (Gaumann et al., 2001) provided evidence that induction of BAX can occur independently of P53. Here we demonstrated that the expression of LATS1 is able to up-regulate the level of the BAX protein without up-regulating the level of P53 and Lats1-mediated induction of BAX is not at a transcriptional level. Therefore, it appears that, at least in the human breast tumor cell MCF-7 and NSCLC cell H460, Lats1-mediated up-regulation of BAX neither relies on p53-mediated activation of the BAX gene nor acts at the transcriptional level. One possible explanation could be that expression of the LATS1 protein stabilizes BAX to induce apoptosis while LATS1 blocks cells at G2/M by promoting the degradation of Cyclin A and cyclin B. More detailed investigation is needed to fully characterize the mechanisms by which LATS1 regulates apoptosis. In summary, our results indicate that the LATS1 tumor suppressor may play an important role in the control of human tumor development and that LATS1 suppresses tumorigenesis by negatively regulating cell proliferation and modulating cell survival.
Materials and methods

Cell cultures
The human embryonic kidney cell line, 293, from America Type Culture Collection was cultured in Dulbecco's Modi®ed Eagle's Medium (DMEM) with 10% fetal bovine serum (FBS) at 378C, 5% CO 2 . The human breast cancer cell line, MCF-7, was a gift from Dr Je Miller and grown in DMEM with 10% FBS. The human non-small cell lung cancer cell line, H460, was from Dr Robert Kratzke and grown in RPMI1640 with 10% FBS and was infected by the recombinant adenovirus at MOI 1 : 300 for Western blot analysis.
Production of replication defective recombinant adenovirus
An adenovirus expression system was purchased from Microbix Biosystems, Inc. (Canada). The EGFP (enhanced green¯uorescent protein) expression adenovirus vector, pCA14-IG, was constructed by subcloning an NcoI ± SalI fragment containing IRES (internal ribosome entry site)-EGFP from plasmid MigR1 (Pear et al., 1998) into pCA14. pCA14-LATS1-IG was constructed by inserting a 3.8 kb human LATS1 cDNA fragment containing the whole coding sequence upstream of the IRES in pCA14-IG. pCA14-LATS1-IG (or vector pCA14-IG only) and pJM17 (a defective adenoviral genome plasmid) were co-transfected into low passage 293 cells using the calcium phosphate precipitation method to produce replication defective recombinant adenoviruses Ad-LATS1 and Ad-EGFP according to manufacturers' instructions. In Ad-LATS1 K734M and Ad-LATS1 S909A , two residues in the LATS1 kinase domain, Lys 734 and Ser 909, which are conserved in kinase domains of all Ser/Thr kinases from yeast to human, were mutated into Met and Ala, respectively, using site-directed mutagenesis (Promega).
Growth inhibition study of MCF-7 cells
MCF-7 cells were infected by Ad-LATS1 or Ad-EGFP at a multiplicity of infection (MOI) of 1 : 50 for 12 h. 485% of the cells were infected as determined by¯ow cytometry (Becton Dickinson, CA, USA) using EGFP as a marker 36 h after infection. 10 4 infected MCF-7 cells were replated in 35 mm dishes and the total number of cells was counted daily using a hemacytometer. For cell cycle pro®le analysis, Both adherent and non-adherent cells were harvested at day 3 or day 4 after virus infection, stained with propidium iodide and analysed by FACS (Becton Dickinson). All data from FACS were analysed with Cellquest software (Becton Dickinson).
Soft agar and nude mice studies
Six hours after adenovirus infection (MOI 1 : 50), 1610 5 MCF-7 cells were replated in 4 ml of 0.35% agarose (SeaPlaque, FMC BioProducts) in DMEM with 10% FBS. Infected MCF-7 cells were allowed to grow for 5 weeks. The colonies were stained with MTT (Aftab et al., 1997) for photographing and colony counting. To access the tumorigenicity of Ad-LATS1-transduced MCF-7 cells in vivo, 5610 6 of Ad-LATS1-transduced MCF-7 cells (in 100 ml of PBS) were injected at the right¯ank of athymic mice that were treated with Estrogen (17b-Estradiol, Innovative Research American) as described by Le et al. (1998) . Ad-EGFP-transduced cells were injected at the left¯ank as the control. Tumors were allowed to develop for 10 weeks.
Cell synchronization
To synchronize cells, the method described by Wright et al. (1999) was followed with minor modi®cation. Brie¯y, cells were seeded at low density and infected with Ad-LATS1 or Ad-EGFP at MOI 1 : 50 for 12 h and allowed to recover for 24 h. The cells were then serum-starved in leucine-free medium (Cellgro). Thirty-six hours later, cells were stimulated with 10% FBS and 2 mg/ml aphidicolin (ICN Biomedicals). After 24 h, the cells were washed to remove excess aphidicolin and 10% FBS DMEM was added. The cells were harvested at various time points and stained with propidium iodide (PI) for DNA content analysis by FACS.
Assessment of cell death
For the Annexin V binding assay, MCF-7 cells were infected by Ad-LATS1 or Ad-EGFP at MOI 1 : 4 for 24 h. Four days after virus infection, the adherent cells were harvested and stained with PE-labeled annexin V and 7AAD (7-aminoactinomycin D, PharMingen) following manufacturer's instructions and EGFP positive (adenovirus infected) cells were gated for further FACS analysis. For the TUNEL assay and DNA content analysis, the cells were infected at MOI 1 : 10. At day 4 post infection, both adherent and non-adherent cells were harvested and stained with PI for DNA content analysis by FACS. Only adherent cells were used for the TUNEL assay with in situ Cell Death Detection Kit (Roche Molecular Biochemicals). The number of TUNEL positive cells and total cells were counted in four random microscopic ®elds at 2006 magni®cation.
Western blot analysis and H1 kinase assay MCF-7 cells infected by Ad-LATS1 or Ad-EGFP (MOI 1 : 50) were cultured for desired times. The cells were lysed in TG buer with 1 mm PMSF, 16 complete proteinase inhibitors (Roche Molecular Biochemicals). 30 ± 120 mg of cell lysate proteins were used for Western blot. Anti-human LATS1 antibody (mAb609) was described by Tao et al. (1999) . Anti-human CDC2, CDK2, Cyclin A, cyclin B, p21, p27 were purchased from Santa Cruz. Anti-P53 antibodies (Ab-6) were purchased from Oncogene. For the histone H1 kinase assay, CDC2 proteins were immunoprecipitated from cell lysates with anti-cyclin B antibody. Kinase assay was performed as described by Tao et al. (1999) .
Quantitative RT PCR analysis
Quantitative real-time RT ± PCR ampli®cation (ABI PRISM 7700 Sequence Detector, Applied Biosystems) was used to quantify the BAX mRNA using Pre-Developed TagMan assay Reagents/Human Bax (Applied Biosystems, Cat. No. 4318283T). Human beta-actin was served as an internal control (Pre-Developed TagMan assay Reagents/Human beta-actin, Applied Biosystems, Cat. No. 4310881E). Four days after virus infection, MCF-7 cells were harvested to isolate total RNAs using RNeasy Kit (Qiagene). The RT ± PCR conditions described by the manufacturer were followed exactly. PCR results were analysed with the ABI PRISM 7700 Sequence Detector software 1.6 (Applied Biosystems).
